Topical hydroquinone in the treatment of some hyperpigmentary disorders
Article first published online: 5 JAN 2002
International Journal of Dermatology
Volume 37, Issue 6, pages 449–450, June 1998
How to Cite
Amer, M. and Metwalli, M. (1998), Topical hydroquinone in the treatment of some hyperpigmentary disorders. International Journal of Dermatology, 37: 449–450. doi: 10.1046/j.1365-4362.1998.00499.x
- Issue published online: 5 JAN 2002
- Article first published online: 5 JAN 2002
Seventy patients (50 with melasma, 10 with freckles, and 10 with post-inflammatory hyperpigmentation) were admitted to this trial. Treatment in the form of 4% hydroquinone (HQ) was applied topically twice daily for a maximum of 12 weeks. Patients were advised to avoid sun exposure and/or to use topical sunscreen during the entire period of treatment.
All patients were examined at week 0 and at weeks 4, 8, and 12 of therapy. At each visit, the lesion size was determined and the pigmentary intensity of melasma, freckles, and the area of post-inflammatory hyperpigmentation (PIH) relative to a non-affected area of skin was rated on a four-point scale: 1, no difference; 2, mild pigmentation; 3, moderate pigmentation; 4, severe pigmentation. At the last visit, the overall response was rated as excellent, good, fair, or poor.